{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:51:25Z","timestamp":1781153485894,"version":"3.54.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA0691006"],"award-info":[{"award-number":["2025GXNSFAA0691006"]}]},{"name":"the Western Medicine Research Project of Guangxi Health Commission","award":["Z-K20241735"],"award-info":[{"award-number":["Z-K20241735"]}]},{"name":"the Western Medicine Research Project of Guangxi Health Commission","award":["Z-K20241734"],"award-info":[{"award-number":["Z-K20241734"]}]},{"name":"Guangxi Science and Technology Major Project","award":["GuikeAA22096030"],"award-info":[{"award-number":["GuikeAA22096030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-35351-6","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T01:54:11Z","timestamp":1768614851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying the potential anti-lung cancer targets of Baicalein using a network pharmacology approach"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiaoping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"4","key":"35351_CR1","first-page":"250","volume":"91","author":"K M Latimer","year":"2015","unstructured":"Latimer, K. M. Lung cancer: diagnosis, treatment principles, and screening\u00a0. Am. Family Phys. 91(4), 250\u2013256 (2015).","journal-title":"Am. Family Phys."},{"key":"35351_CR2","first-page":"487","volume-title":"Lung Cancer: Diagnosis, Treatment Principles, and Screening","author":"J Kim","year":"2022","unstructured":"Kim, J., Lee, H. & Huang, B. W. Lung Cancer: Diagnosis, Treatment Principles, and Screening Vol. 105, 487\u2013494 (American family physician, 2022)."},{"issue":"3","key":"35351_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. & Laversanne, M. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries\u00a0. Cancer J. Clin. 74(3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"issue":"24","key":"35351_CR4","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Comparative analysis of cancer statistics in China and the united States in 2024. Chin. Med. J. 137(24), 3093\u20133100 (2024).","journal-title":"Chin. Med. J."},{"key":"35351_CR5","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN\u00a0. Cancer Epidemiol. 93, 102693 (2024).","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"35351_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"R L Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics. Cancer J. Clin. 75(1), 10\u201345 (2025).","journal-title":"Cancer J. Clin."},{"key":"35351_CR7","doi-asserted-by":"crossref","unstructured":"Gao, Q. et al. Synergistic strategies for lung cancer immunotherapy: combining phytochemicals and immune-checkpoint inhibitors\u00a0 (PTR, 2025).","DOI":"10.1002\/ptr.8482"},{"key":"35351_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.33393\/dti.2024.2707","volume":"18","author":"K Munjal","year":"2024","unstructured":"Munjal, K. et al. Molecular targets and therapeutic potential of baicalein: a review\u00a0. Drug target. Insights 18, 30\u201346 (2024).","journal-title":"Drug target. Insights"},{"issue":"23","key":"35351_CR9","doi-asserted-by":"publisher","first-page":"e40809","DOI":"10.1016\/j.heliyon.2024.e40809","volume":"10","author":"M Hegde","year":"2024","unstructured":"Hegde, M. Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment\u00a0. Heliyon 10(23), e40809 (2024).","journal-title":"Heliyon"},{"key":"35351_CR10","first-page":"116862","volume-title":"The most recent progress of baicalein in its anti-neoplastic effects and mechanisms\u00a0","author":"C Lei","year":"2024","unstructured":"Lei, C. et al. The most recent progress of baicalein in its anti-neoplastic effects and mechanisms\u00a0 Vol. 176, 116862 (Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, 2024)."},{"key":"35351_CR11","first-page":"151","volume-title":"Natural compounds: A new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer\u00a0","author":"X Zhou","year":"2022","unstructured":"Zhou, X. & Wang, X. Natural compounds: A new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer\u00a0 151 (Biomedicine & Pharmacotherapy, 2022)."},{"issue":"9","key":"35351_CR12","doi-asserted-by":"publisher","first-page":"e14230","DOI":"10.1111\/jfbc.14230","volume":"46","author":"N. Chandrashekar","year":"2022","unstructured":"Chandrashekar, N. . A review on its anti-cancer effects and mechanisms in lung carcinoma\u00a0. J. Food Biochem. 46(9), e14230 (2022).","journal-title":"J. Food Biochem."},{"issue":"7","key":"35351_CR13","doi-asserted-by":"publisher","first-page":"e23053","DOI":"10.1002\/jbt.23053","volume":"36","author":"N Chandrashekar","year":"2022","unstructured":"Chandrashekar, N., Subramanian, R. & Thiruvengadam, D. Baicalein inhibits cell proliferation and enhances apoptosis in human A549 cells and benzo(a)pyrene-induced pulmonary carcinogenesis in mice\u00a0. J. Biochem. Mol. Toxicol. 36(7), e23053 (2022).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"35351_CR14","first-page":"110965","volume-title":"Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3\u00a0","author":"J Li","year":"2021","unstructured":"Li, J. et al. Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3\u00a0 Vol. 133, 110965 (Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, 2021)."},{"issue":"10","key":"35351_CR15","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.3390\/ijerph18105243","volume":"18","author":"Alsharairi N A","year":"2021","unstructured":"Alsharairi N A. Scutellaria baicalensis and their natural flavone compounds as potential medicinal drugs for the treatment of nicotine-induced non-small-cell lung cancer and asthma\u00a0. Int. J. Environ. Res. Public Health 18(10), 5243 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"35351_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2147\/OTT.S261071","volume":"14","author":"Y MA","year":"2021","unstructured":"MA, Y. et al. Anti-Lung cancer targets of radix paeoniae rubra and biological molecular mechanism: network Pharmacological analyses and experimental validation [J]. OncoTargets Therapy. 14, 1925\u20131936 (2021).","journal-title":"OncoTargets Therapy"},{"issue":"6","key":"35351_CR17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s10753-013-9703-2","volume":"36","author":"G.W FAN","year":"2013","unstructured":"FAN, G. .W. et al. Anti-inflammatory activity of Baicalein in LPS-stimulated RAW264.7 macrophages via Estrogen receptor and NF-\u03baB-dependent pathways. Inflammation 36(6), 1584\u20131591 (2013).","journal-title":"Inflammation"},{"issue":"4","key":"35351_CR18","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/jcmm.13556","volume":"22","author":"C Lu","year":"2018","unstructured":"Lu, C. et al. Baicalein inhibits cell growth and increases cisplatin sensitivity of A549 and H460 cells via miR-424-3p and targeting PTEN\/PI3K\/Akt pathway. J. Cell. Mol. Med. 22(4), 2478\u20132487 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"35351_CR19","first-page":"112105","volume-title":"Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective Vol. 143, 112105 (Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, 2021)."},{"key":"35351_CR20","doi-asserted-by":"crossref","unstructured":"Hao, B. et al. Baicalein tethers CD274\/PD-L1 for autophagic degradation to boost antitumor immunity . Autophagy, : 1\u201317. (2024).","DOI":"10.1080\/15548627.2024.2439657"},{"issue":"10","key":"35351_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/nbt1007-1110","volume":"25","author":"Hopkins A L","year":"2007","unstructured":"Hopkins A L. Network Pharmacology\u00a0. Nat. Biotechnol. 25(10), 1110\u20131111 (2007).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"35351_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13020-024-01056-z","volume":"20","author":"Y Zhai","year":"2025","unstructured":"Zhai, Y. et al. Network pharmacology: a crucial approach in traditional Chinese medicine research. Chin. Med. 20(1), 8 (2025).","journal-title":"Chin. Med."},{"key":"35351_CR23","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","volume":"309","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J. Ethnopharmacol. 309, 116306 (2023).","journal-title":"J. Ethnopharmacol."},{"issue":"7","key":"35351_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12032-025-02811-4","volume":"42","author":"Z Zhao","year":"2025","unstructured":"Zhao, Z. et al. Cancer network pharmacology: multi-network regulatory mechanisms and future directions. Medical oncol. 42(7), 255 (2025).","journal-title":"Medical oncol."},{"issue":"1","key":"35351_CR25","first-page":"1","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin. J. Nat. Med. 19(1), 1\u201311 (2021).","journal-title":"Chin. J. Nat. Med."},{"issue":"4","key":"35351_CR26","first-page":"572","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Exploration of compatibility rules and discovery of active ingredients in TCM formulas by network Pharmacology\u00a0. Chin. Herb. Med. 16(4), 572\u2013588 (2024).","journal-title":"Chin. Herb. Med."},{"key":"35351_CR27","doi-asserted-by":"crossref","unstructured":"Xu G. et al. Systematic Analysis Strategy Based on Network Pharmacology to Investigate the Potential Mechanism of Fritillaria thunbergii Miq. against Idiopathic Pulmonary Fibrosis [J]. Evidence-based complementary and alternative medicine: eCAM, 2022: 2996878. (2022).","DOI":"10.1155\/2022\/2996878"},{"key":"35351_CR28","doi-asserted-by":"publisher","first-page":"112125","DOI":"10.1016\/j.jep.2019.112125","volume":"243","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Hyphenated chromatography detection and compound-target-disease investigation on herb-pair Chuanxiong rhizoma - Xiangfu rhizoma\u00a0. J. Ethnopharmacol. 243, 112125 (2019).","journal-title":"J. Ethnopharmacol."},{"issue":"11","key":"35351_CR29","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498\u20132504 (2003).","journal-title":"Genome Res."},{"issue":"Suppl 4","key":"35351_CR30","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C H Chin","year":"2014","unstructured":"Chin, C. H. et al. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(Suppl 4), S11 (2014).","journal-title":"BMC Syst. Biol."},{"key":"35351_CR31","doi-asserted-by":"crossref","unstructured":"WU, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data . (2021). (Cambridge (Mass)), 2(3): 100141 .","DOI":"10.1016\/j.xinn.2021.100141"},{"issue":"5","key":"35351_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"A. M Newman","year":"2015","unstructured":"Newman, A. . M. et al. Robust enumeration of cell subsets from tissue expression profiles\u00a0. Nat. Methods 12(5), 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"issue":"11","key":"35351_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A. et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer\u00a0. Genome Res. 28(11), 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"35351_CR34","doi-asserted-by":"crossref","unstructured":"Alexander, N. & Woetzel, N. Meiler J. bcl::Cluster: A method for clustering biological molecules coupled with visualization in the Pymol Molecular Graphics System [J]. IEEE International Conference on Computational Advances in Bio and Medical Sciences : [proceedings] IEEE International Conference on Computational Advances in Bio and Medical Sciences, 2011: 13\u2009\u2013\u20098. (2011).","DOI":"10.1109\/ICCABS.2011.5729867"},{"issue":"16","key":"35351_CR35","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility\u00a0. J. Comput. Chem. 30(16), 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"issue":"2","key":"35351_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. AutoDock vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading\u00a0. J. Comput. Chem. 31(2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"35351_CR37","doi-asserted-by":"crossref","unstructured":"Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers [J]. SoftwareX, 1\u20132: 19\u201325. (2015).","DOI":"10.1016\/j.softx.2015.06.001"},{"issue":"25","key":"35351_CR38","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huand","year":"2013","unstructured":"Huand, J. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data\u00a0. J. Comput. Chem. 34(25), 2135\u20132145 (2013).","journal-title":"J. Comput. Chem."},{"issue":"4","key":"35351_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31(4), 671\u2013690 (2010).","journal-title":"J. Comput. Chem."},{"issue":"12","key":"35351_CR40","first-page":"1250","volume":"6","author":"GZ Cheng","year":"2000","unstructured":"Cheng, G. Z. et al. Targeting the phosphatidylinositol-3 kinase\/Akt pathway for the treatment of cancer. Current opinion in investigational drugs 6(12), 1250\u20138 (2000).","journal-title":"Current opinion in investigational drugs"},{"key":"35351_CR41","doi-asserted-by":"publisher","first-page":"154852","DOI":"10.1016\/j.prp.2023.154852","volume":"251","author":"Almalki W H","year":"2023","unstructured":"Almalki W H. Beyond the genome: LncRNAs as regulators of the PI3K\/AKT pathway in lung cancer. Pathol. Res. Pract. 251, 154852 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"35351_CR42","first-page":"583929","volume":"2011","author":"A Mogi","year":"2011","unstructured":"Mogi, A. & Kuwano, H. TP53 mutations in nonsmall cell lung cancer\u00a0. J. Biomed. Biotechnol. 2011, 583929 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"35351_CR43","doi-asserted-by":"crossref","unstructured":"Tornesello, M. L. TP53 mutations in cancer: molecular features and therapeutic opportunities (Review) . Int. J. Mol. Med., 55(1). (2025).","DOI":"10.3892\/ijmm.2024.5448"},{"issue":"5","key":"35351_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","volume":"14","author":"Anderson N G","year":"2002","unstructured":"Anderson N G. The protein kinase B\/Akt signalling pathway in human malignancy\u00a0. Cell. Signal. 14(5), 381\u2013395 (2002).","journal-title":"Cell. Signal."},{"issue":"1","key":"35351_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1164\/rccm.200707-1022OC","volume":"178","author":"X Xu C","year":"2008","unstructured":"Xu C, X. & Jin, Jered. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis\u00a0. Am. J. Respir. Crit Care Med. 178(1), 60\u201373 (2008).","journal-title":"Am. J. Respir. Crit Care Med."},{"issue":"15","key":"35351_CR46","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/onc.2010.556","volume":"30","author":"MC Hollander","year":"2011","unstructured":"Hollander, M. C. et al. Akt1 deletion prevents lung tumorigenesis by mutant K-ras\u00a0. Oncogene 30(15), 1812\u20131821 (2011).","journal-title":"Oncogene"},{"key":"35351_CR47","doi-asserted-by":"crossref","unstructured":"Taherkhani, A. et al. Samie L,. Flavonoids as Strong Inhibitors of MAPK3: A Computational Drug Discovery Approach [J]. International journal of analytical chemistry, 2023: 8899240. (2023).","DOI":"10.1155\/2023\/8899240"},{"issue":"6","key":"35351_CR48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ccell.2015.04.010","volume":"27","author":"B Han","year":"2015","unstructured":"Han, B. et al. Small-Molecule Bcl2 BH4 antagonist for lung cancer therapy\u00a0. Cancer cell. 27(6), 852\u2013863 (2015).","journal-title":"Cancer cell."},{"issue":"1","key":"35351_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler, M. et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy\u00a0. Signal. Transduct. Target. Therapy 10(1), 91 (2025).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"8","key":"35351_CR50","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00204-015-1524-7","volume":"89","author":"K SUDA","year":"2015","unstructured":"SUDA, K. & MITSUDOMI, T. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity [J]. Arch. Toxicol. 89 (8), 1227\u20131240 (2015).","journal-title":"Arch. Toxicol."},{"key":"35351_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3599832","author":"P Yang","year":"2022","unstructured":"Yang, P. & Li, W. SHC1 promotes lung cancer metastasis by interacting with EGFR. J. oncol https:\/\/doi.org\/10.1155\/2022\/3599832 (2022).","journal-title":"J. oncol"},{"issue":"1","key":"35351_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"35351_CR53","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1021\/acs.jcim.8b00312","volume":"58","author":"Gaillard T","year":"2018","unstructured":"Gaillard T. Evaluation of AutoDock and AutoDock Vina on the CASF-2013 benchmark\u00a0. J. Chem. Inf. Model. 58(8), 1697\u20131706 (2018).","journal-title":"J. Chem. Inf. Model."},{"issue":"7","key":"35351_CR54","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2174\/0113816128330427241017110325","volume":"31","author":"J Yang","year":"2025","unstructured":"Yang, J. et al. Unraveling the core components and critical targets of houttuynia cordata Thunb. In treating Non-small cell lung cancer through network Pharmacology and Multi-omics analysis\u00a0. Curr. Pharm. Design 31(7), 540\u2013558 (2025).","journal-title":"Curr. Pharm. Design"},{"issue":"9","key":"35351_CR55","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00894-009-0454-9","volume":"15","author":"E Durham","year":"2009","unstructured":"Durham, E. et al. Solvent accessible surface area approximations for rapid and accurate protein structure prediction. J. Mol. Model. 15(9), 1093\u20131108 (2009).","journal-title":"J. Mol. Model."},{"key":"35351_CR56","doi-asserted-by":"publisher","first-page":"1619517","DOI":"10.3389\/fphar.2025.1619517","volume":"16","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib. Front. Pharmacol. 16, 1619517 (2025).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"35351_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamaoncol.2024.5381","volume":"11","author":"JS Mandelblatt","year":"2025","unstructured":"Mandelblatt, J. S. et al. Estimation of cancer deaths averted from prevention, screening, and treatment Efforts, 1975\u20132020\u00a0. JAMA Oncol. 11(2), 162\u2013167 (2025).","journal-title":"JAMA Oncol."},{"key":"35351_CR58","doi-asserted-by":"crossref","unstructured":"NEW, M. KEITH R. Early detection and chemoprevention of lung cancer . F1000Research, 7: 61. (2018).","DOI":"10.12688\/f1000research.12433.1"},{"issue":"5","key":"35351_CR59","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/CM9.0000000000002991","volume":"137","author":"T Barr","year":"2024","unstructured":"Barr, T. et al. Recent advances and remaining challenges in lung cancer therapy\u00a0. Chin. Med. J. 137(5), 533\u2013546 (2024).","journal-title":"Chin. Med. J."},{"key":"35351_CR60","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani, H. et al. Immunotherapy in lung cancer: current landscape and future directions\u00a0. Front. Immunol. 13, 823618 (2022).","journal-title":"Front. Immunol."},{"key":"35351_CR61","doi-asserted-by":"publisher","first-page":"1022705","DOI":"10.3389\/fonc.2022.1022705","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases\u00a0. Front. Oncol. 12, 1022705 (2022).","journal-title":"Front. Oncol."},{"key":"35351_CR62","first-page":"e14623","volume-title":"Baicalein Targets MAPK9 to Induce apoptosis of hepatocellular carcinoma cells\u00a0","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Baicalein Targets MAPK9 to Induce apoptosis of hepatocellular carcinoma cells\u00a0 Vol. 104, e14623 (Chemical biology & drug design, 2024)."},{"issue":"2","key":"35351_CR63","first-page":"783","volume":"19","author":"Y Xie","year":"2019","unstructured":"Xie, Y. & Shi, X. PI3K\/Akt signaling transduction pathway, erythropoiesis and Glycolysis in hypoxia (Review)\u00a0. Mol. Med. Rep. 19(2), 783\u2013791 (2019).","journal-title":"Mol. Med. Rep."},{"issue":"23","key":"35351_CR64","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1002\/cam4.4794","volume":"11","author":"Z Zou","year":"2022","unstructured":"Zou, Z. et al. KBTBD7 promotes non-small cell lung carcinoma progression by enhancing ubiquitin-dependent degradation of PTEN\u00a0. Cancer Med. 11(23), 4544\u20134554 (2022).","journal-title":"Cancer Med."},{"issue":"3","key":"35351_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","volume":"28","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer\u00a0. Clin. Cancer Research: Official J. Am. Association Cancer Res. 28(3), 526\u2013539 (2022).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"issue":"3","key":"35351_CR66","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cbin.11962","volume":"47","author":"T Yuan","year":"2023","unstructured":"Yuan, T. et al. Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression. Cell. Biol. Int. 47(3), 622\u2013633 (2023).","journal-title":"Cell. Biol. Int."},{"key":"35351_CR67","doi-asserted-by":"publisher","first-page":"1516583","DOI":"10.3389\/fphar.2025.1516583","volume":"16","author":"M Qiang","year":"2025","unstructured":"Qiang, M. et al. Targeting the PI3K\/AKT\/mTOR pathway in lung cancer: mechanisms and therapeutic targeting\u00a0. Front. Pharmacol. 16, 1516583 (2025).","journal-title":"Front. Pharmacol."},{"key":"35351_CR68","first-page":"821485","volume":"12","author":"CA Zhou","year":"2021","unstructured":"Zhou, C. A. et al. A mixture of Baicalein, Wogonin, and Oroxylin-A inhibits EMT in the A549 cell line via the PI3K\/AKT-TWIST1-Glycolysis pathway\u00a0. Front. Pharmacol. 12, 821485 (2021).","journal-title":"Front. Pharmacol."},{"key":"35351_CR69","first-page":"677","volume-title":"Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K\/Akt\/NF-\u03baB pathway\u00a0","author":"M Yu","year":"2017","unstructured":"Yu, M. et al. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K\/Akt\/NF-\u03baB pathway\u00a0 Vol. 90, 677\u2013685 (Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, 2017)."},{"issue":"10","key":"35351_CR70","doi-asserted-by":"publisher","first-page":"e109705","DOI":"10.1371\/journal.pone.0109705","volume":"9","author":"M Rehan","year":"2014","unstructured":"Rehan, M. et al. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206\u00a0. PLoS One 9(10), e109705 (2014).","journal-title":"PLoS One"},{"issue":"5 Suppl","key":"35351_CR71","doi-asserted-by":"publisher","first-page":"141s","DOI":"10.1378\/chest.125.5_suppl.141S-a","volume":"125","author":"JM Kurie","year":"2004","unstructured":"Kurie, J. M. Role of protein kinase B-dependent signaling in lung tumorigenesis\u00a0. Chest 125(5 Suppl), 141s\u20134s (2004).","journal-title":"Chest"},{"issue":"4","key":"35351_CR72","first-page":"1472","volume":"2","author":"X Xu","year":"2010","unstructured":"Xu, X. et al. Roles of protein kinase B\/Akt in lung cancer\u00a0. Frontiers. Biosci. 2(4), 1472\u20131484 (2010).","journal-title":"Frontiers. Biosci."},{"issue":"1","key":"35351_CR73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-022-01662-1","volume":"21","author":"X Tian","year":"2022","unstructured":"Tian, X. et al. Costunolide is a dual inhibitor of MEK1 and AKT1\/2 that overcomes osimertinib resistance in lung cancer. Mol. Cancer 21(1), 193 (2022).","journal-title":"Mol. Cancer"},{"issue":"10","key":"35351_CR74","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/j.1349-7006.2011.02025.x","volume":"102","author":"MW Lee","year":"2011","unstructured":"Lee, M. W. et al. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration\u00a0. Cancer Sci. 102(10), 1822\u20131828 (2011).","journal-title":"Cancer Sci."},{"key":"35351_CR75","doi-asserted-by":"crossref","unstructured":"CHIBAYA, L. et al. Mdm2 Phosphorylation by Akt Regulates the p53 Response To Oxidative Stress To Promote Cell Proliferation and Tumorigenesis Vol. 118 (Proc Natl Acad Sci U S A, 2021). 4.","DOI":"10.1073\/pnas.2003193118"},{"issue":"5","key":"35351_CR76","first-page":"3100","volume":"41","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen species\u2013induced autophagic death\u00a0. Oncol. Rep. 41(5), 3100\u20133110 (2019).","journal-title":"Oncol. Rep."},{"key":"35351_CR77","doi-asserted-by":"publisher","first-page":"650780","DOI":"10.3389\/fphar.2021.650780","volume":"12","author":"G Zhu","year":"2021","unstructured":"Zhu, G. et al. The key target and molecular mechanism of the volatile component of scutellaria baicalensis Georgi in acute lung injury based on network Pharmacology\u00a0. Front. Pharmacol. 12, 650780 (2021).","journal-title":"Front. Pharmacol."},{"key":"35351_CR78","doi-asserted-by":"publisher","first-page":"1526952","DOI":"10.3389\/fphar.2025.1526952","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA\/PI3K\/AKT pathway\u00a0. Front. Pharmacol. 16, 1526952 (2025).","journal-title":"Front. Pharmacol."},{"key":"35351_CR79","first-page":"64","volume-title":"The role of BIM-EL and BCL2-\u03b1 on the efficacy of erlotinib and gefitinib in lung cancer\u00a0","author":"J Simasi","year":"2015","unstructured":"Simasi, J. et al. The role of BIM-EL and BCL2-\u03b1 on the efficacy of erlotinib and gefitinib in lung cancer\u00a0 Vol. 209, 64\u201368 (Respiratory physiology & neurobiology, 2015)."},{"issue":"6","key":"35351_CR80","doi-asserted-by":"publisher","first-page":"e0158395","DOI":"10.1371\/journal.pone.0158395","volume":"11","author":"MS Hung","year":"2016","unstructured":"Hung, M. S. et al. Epidermal growth factor receptor mutation enhances expression of cadherin-5 in lung cancer cells. PLoS One 11(6), e0158395 (2016).","journal-title":"PLoS One"},{"key":"35351_CR81","doi-asserted-by":"publisher","first-page":"104270","DOI":"10.1016\/j.phrs.2019.104270","volume":"145","author":"A Alwhaibi","year":"2019","unstructured":"Alwhaibi, A. et al. The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis\u00a0. Pharmacol. Res. 145, 104270 (2019).","journal-title":"Pharmacol. Res."},{"issue":"1","key":"35351_CR82","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1038\/s41598-017-06128-9","volume":"7","author":"G Rao","year":"2017","unstructured":"Rao, G. et al. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations\u00a0. Sci. Rep. 7(1), 7066 (2017).","journal-title":"Sci. Rep."},{"issue":"1","key":"35351_CR83","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13277-015-3893-1","volume":"37","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors\u00a0. Tumour Biology: J. Int. Soc. Oncodevelopmental Biology Med. 37(1), 1061\u20131069 (2016).","journal-title":"Tumour Biology: J. Int. Soc. Oncodevelopmental Biology Med."},{"key":"35351_CR84","doi-asserted-by":"publisher","first-page":"1405521","DOI":"10.3389\/fphar.2024.1405521","volume":"15","author":"T Chen","year":"2024","unstructured":"Chen, T. et al. Synergistic antitumor activity of Baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K\/Akt pathway\u00a0. Front. Pharmacol. 15, 1405521 (2024).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"35351_CR85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bcp.2014.09.019","volume":"92","author":"SD Kim","year":"2014","unstructured":"Kim, S. D. et al. Baicalein inhibits agonist- and tumor cell-induced platelet aggregation while suppressing pulmonary tumor metastasis via cAMP-mediated VASP phosphorylation along with impaired MAPKs and PI3K-Akt activation\u00a0. Biochem. Pharmacol. 92(2), 251\u2013265 (2014).","journal-title":"Biochem. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35351-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:03:25Z","timestamp":1770638605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35351-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35351"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35351-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The KEGG pathway map (Fig.\u00a05) used in this article has been authorized by the KEGG database under written permission (Permission ID: 254132). The permission document has been submitted along with the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are accountable for all aspects of the work and ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All data used in this study was obtained from public datasets. Our research conformed to the principles of the Helsinki Declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"5527"}}